Modalis Therapeutics

Developer of CRISPR based therapeutics for monogenic disorders

placeTokyo, Tokyo, Japan calendar_todayFounded 2016 groups29 employees language modalistx.com

Registered entities

Innovation

19 patent families (5 granted) — focus: Chemistry & metallurgy, Human necessities; filing pace slowing. Cited 516 times.

YearFilings
20191
20205
202111
202213
20238
20243
20254

Social engagement

Social engagement: 4.5K social following, 4 posts in the last 12 months — below the industry typical range.

Investor mix

17 investors on record; lead investors include UTokyo Innovation Platform, Green Pine Capital Partners, LAV Asset Management, Pegasus Tech Ventures; 2 have since exited.

Investor typeCountShare
Venture capital1165%
Private equity318%
Other / undisclosed318%

Recent activity

6 Jul 2025
Partnership
Broad Institute
Coming soon